Somatostatin Receptor Imaging in Differentiated Thyroid Cancer

  • Levent KabasakalEmail author
  • Onur Erdem Şahin


Most of the thyroid cancers consist of differentiated thyroid cancers (DTCs). Generally having a good prognosis, with the surgery and radioactive iodine (RAI) treatment in selected patients, a good outcome can be obtained. In contrast, some DTC patients are resistant to RAI (RAI-R). Treatment options for RAI-R patients are restricted. On the other hand, local limited RAI-R DTC patients have a chance of surgical operation and external radiotherapy. In addition, early detection of lesions and initial surgery are critical points in the management of the disease. FDG-PET imaging is a modality used in high-risk patients with elevated Tg. However, FDG-PET imaging in some patients may fail to detect the lesion.

The monitoring of somatostatin receptor (SSTR) expression in DTC cells allows the use of somatostatin receptor scintigraphy in DTC patients. Somatostatin receptor scintigraphy demonstrated to be positive in FDG-negative DTC patients provided an effective imaging method for lesion detection in those patients. In addition, patients with positive Tc-99m-labeled somatostatin receptor imaging have an operative chance with an intraoperative gamma probe. This modality increases the chances of success in patients with a history of multiple operations. Also in patients with positive somatostatin receptor scintigraphy, Lu-177-labeled or Y-90-labeled somatostatin analogs constitute a new treatment option.




  1. 1.
    Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metabol. 2006;91:2892–9. Scholar
  2. 2.
    Lorusso L, Pieruzzi L, Biagini A, Sabini E, Valerio L, Giani C, et al. Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer. Onco Targets Ther. 2016;9:6467–77. Scholar
  3. 3.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. Scholar
  4. 4.
    Ain KB, Taylor KD, Tofiq S, Venkataraman G. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab. 1997;82:1857–62. Scholar
  5. 5.
    Tenenbaum F, Lumbroso J, Schlumberger M, Caillou B, Fragu P, Parmentier C. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma. J Nucl Med. 1995;36:807–10.PubMedGoogle Scholar
  6. 6.
    Kundu P, Lata S, Sharma P, Singh H, Malhotra A, Bal C. Prospective evaluation of 68Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative 131I-whole body scan: comparison with 18F-FDG PET-CT. Eur J Nucl Med Mol Imaging. 2014;41:1354–62. Scholar
  7. 7.
    Middendorp M, Selkinski I, Happel C, Kranert WT, Grunwald F. Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data. Q J Nucl Med Mol Imaging. 2010;54:76–83.PubMedGoogle Scholar
  8. 8.
    Traub-Weidinger T, Putzer D, von Guggenberg E, Dobrozemsky G, Nilica B, Kendler D, et al. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism. Eur J Nucl Med Mol Imaging. 2015;42:1995–2001. Scholar
  9. 9.
    Binse I, Poeppel TD, Ruhlmann M, Ezziddin S, Gorges R, Sabet A, et al. 68Ga-DOTATOC PET/CT in patients with iodine- and 18F-FDG-negative differentiated thyroid carcinoma and elevated serum thyroglobulin. J Nucl Med. 2016;57:1512–7. Scholar
  10. 10.
    Salavati A, Puranik A, Kulkarni HR, Budiawan H, Baum RP. Peptide receptor radionuclide therapy (PRRT) of medullary and nonmedullary thyroid cancer using radiolabeled somatostatin analogues. Semin Nucl Med. 2016;46:215–24. Scholar
  11. 11.
    Na’ara S, Amit M, Fridman E, Gil Z. Contemporary management of recurrent nodal disease in differentiated thyroid carcinoma. Rambam Maimonides Med J. 2016;7:e0006. Scholar
  12. 12.
    Aras G, Gultekin SS, Kucuk NO, Demirer S, Tug T. Intraoperative gamma probe guidance with 99mTc-pertechnetate in the completion thyroidectomy. Ann Nucl Med. 2009;23:421–6. Scholar
  13. 13.
    Terzioglu T, Senyurek YG, Tunca F, Turkmen C, Mudun A, Salmaslioglu A, et al. Excision efficiency of radioguided occult lesion localization in reoperative thyroid and parathyroid surgery. Thyroid. 2010;20:1271–8. Scholar
  14. 14.
    Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using [(6)(8)Ga]PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging. 2015;42:1622–3. Scholar
  15. 15.
    Taywade SK, Damle NA, Bal C. PSMA expression in papillary thyroid carcinoma: opening a new horizon in management of thyroid cancer? Clin Nucl Med. 2016;41:e263–5. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Nuclear Medicine, Cerrahpaşa Faculty of Medicineİstanbul UniversityIstanbulTurkey

Personalised recommendations